Q1 2026 Earnings Call Transcript June 6, 2025 Operator: Good afternoon, ladies and gentlemen. Thank you for joining ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

The company completed a strategic transaction with United Trademark Group in April 2025, providing $3 million in liquidity ...

Growth continues in military and specialty markets; data center revenues are present in Tier 2 and Tier 3 segments but remain ...